Hansa Biopharma AB (HNSBF)
2.93
0.00 (0.00%)
USD |
OTCM |
Sep 20, 16:00
Hansa Biopharma Max Drawdown (5Y): 92.35% for Aug. 31, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| August 31, 2024 | 92.35% |
| July 31, 2024 | 92.35% |
| June 30, 2024 | 92.35% |
| May 31, 2024 | 92.35% |
| April 30, 2024 | 92.35% |
| March 31, 2024 | 92.35% |
| February 29, 2024 | 92.35% |
| January 31, 2024 | 92.35% |
| December 31, 2023 | 92.35% |
| November 30, 2023 | 90.54% |
| October 31, 2023 | 90.54% |
| September 30, 2023 | 87.60% |
| August 31, 2023 | 87.60% |
| July 31, 2023 | 86.76% |
| June 30, 2023 | 86.58% |
| May 31, 2023 | 86.58% |
| April 30, 2023 | 86.58% |
| March 31, 2023 | 86.58% |
| February 28, 2023 | 86.58% |
| January 31, 2023 | 86.58% |
| December 31, 2022 | 86.58% |
| November 30, 2022 | 86.58% |
| October 31, 2022 | 84.24% |
| September 30, 2022 | 84.24% |
| August 31, 2022 | 84.24% |
| Date | Value |
|---|---|
| July 31, 2022 | 84.24% |
| June 30, 2022 | 84.24% |
| May 31, 2022 | 84.24% |
| April 30, 2022 | 83.74% |
| March 31, 2022 | 79.53% |
| February 28, 2022 | 79.53% |
| January 31, 2022 | 79.53% |
| December 31, 2021 | 79.53% |
| November 30, 2021 | 79.53% |
| October 31, 2021 | 79.53% |
| September 30, 2021 | 79.53% |
| August 31, 2021 | 79.53% |
| July 31, 2021 | 79.53% |
| June 30, 2021 | 79.53% |
| May 31, 2021 | 79.53% |
| April 30, 2021 | 79.53% |
| March 31, 2021 | 79.53% |
| February 28, 2021 | 79.53% |
| January 31, 2021 | 79.53% |
| December 31, 2020 | 79.53% |
| November 30, 2020 | 79.53% |
| October 31, 2020 | 79.53% |
| September 30, 2020 | 79.53% |
| August 31, 2020 | 79.53% |
| July 31, 2020 | 79.53% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
62.96%
Minimum
Sep 2019
92.35%
Maximum
Dec 2023
82.86%
Average
79.53%
Median
Dec 2019
Max Drawdown (5Y) Benchmarks
| Abliva AB | 99.34% |
| Karolinska Development AB | -- |
| Calliditas Therapeutics AB | -- |
| Oncopeptides AB | -- |
| BioInvent International AB | 62.75% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -37.84 |
| Beta (5Y) | 0.4481 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 68.00% |
| Historical Sharpe Ratio (5Y) | -0.4665 |
| Historical Sortino (5Y) | -0.7359 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 38.00% |